海博为药业 is a Chengdu-based clinical-stage biopharma focused on innovative drug discovery and development across oncology, pain, and CNS indications. Its pipeline includes clinical programs such as HBW-3220, HBW-3210 and HBW-004285, and the company has laid out more than ten preclinical R&D lines. The firm emphasizes differentiated platforms including brain-penetrant drug development and is advancing third-generation BTK inhibitors, non‑addictive Nav1.8 inhibitors, and an oral KRAS G12D inhibitor. Management highlights rapid clinical progress and early-stage clinical data they describe as promising, and the team is led by Dr. Li Yingfu. Planned use of new capital prioritizes clinical research for the three named molecules and acceleration of multiple preclinical programs toward the clinic and market, including overseas expansion ambitions. The company positions itself to translate laboratory discoveries into clinical and commercial-stage therapies.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024